Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

NanoViricides plans Phase II trial of NV-387 for measles

By Public Technologies
  • NanoViricides announced Nov. 10, 2026, it is developing a Phase II trial protocol for NV-387 in measles, targeting FDA review.
  • Already reported animal studies showed antiviral activity against measles; a completed juvenile mouse study found no treatment-related toxicity.
  • NV-387 remains investigational, with no FDA approval for any disease; it is already in Phase II trials for Ebola and mpox.
  • FDA orphan drug designation offers potential tax credits, fee exemptions and seven years of market exclusivity following approval.
  • Rare pediatric disease designation could yield a transferable priority review voucher upon successful marketing approval, subject to required conditions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611100845ACCESSWRNAPR_____1249304) on November 10, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.